Complete response in anaplastic lymphoma kinase–rearranged oncocytic thyroid cancer:A case report and review of literature

作     者：Victoire de Salins Gokoulakrichenane Loganadane Charlotte Joly Mukedaisi Abulizi Maya Nourieh Hélène Boussion Yazid Belkacemi Christophe Tournigand Emmanuelle Kempf 

作者机构：Department of Medical OncologyHenri Mondor et Albert Chenevier Teaching HospitalAssistance Publique–Hôpitaux de ParisUniversity of Paris-Est CreteilCréteil 94010France Department of Radiation Oncology and Breast CenterHenri Mondor University HospitalAssistance Publique–Hôpitaux de ParisUniversity of Paris-Est Creteil and IMRB-INSERM 955 Team 21Creteil 94010France Department of Nuclear MedicineHenri Mondor et Albert Chenevier Teaching HospitalAssistance Publique–Hôpitaux de ParisUniversity of Paris-Est CreteilCréteil 94010France Department of PathologyHenri Mondor et Albert Chenevier Teaching HospitalAssistance Publique–Hôpitaux de ParisUniversity of Paris-Est CreteilCréteil 94010France 

出 版 物：《World Journal of Clinical Oncology》 (世界临床肿瘤学杂志（英文版）)

年 卷 期：2020年第11卷第7期

页      面：495-503页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Oncocytic tumors of the thyroid Hürthle cell tumors Crizotinib Precision Medicine Case report 

摘      要：BACKGROUND Oncocytic carcinoma of the thyroid is a rare disease,characterized by a poor prognosis and low response rate to radioiodine *** is a specific anaplastic lymphoma kinase(ALK)inhibitor,which was initially developed in non-small cell lung *** solid tumors harboring a translocation in ALK have been described,such as renal carcinoma,thyroid,colorectal,ovarian cancers,and spitzoid *** research of ALK rearrangements in thyroid tumor is a promising therapeutic track,and treatments need to be *** SUMMARY We report the case of a 76-year-old woman with a history of multinodular goiter,who was hospitalized for impairment of her general *** was diagnosed with metastatic oncocytic thyroid *** metastases were found:Multiple mediastinal lymphadenopathies,lytic bone lesions and bilateral mammary *** in situ hybridization analysis revealed an ALK rearrangement in 61%of *** other mutation was found.A tumor board discussion based on molecular characteristics of the tumor suggested initiating a daily treatment by crizotinib,a specific ALK inhibitor.A positron emission tomography scan performed 4 mo after the initiation of crizotinib showed a complete metabolic *** This case highlights an unexpected efficacy of crizotinib in an ALK-rearranged thyroid tumor,and the need of further assessments.